Evidence map›Paper›PMID 40252396›Full record

ArticleCancer treatment and research communications2025

The symptom burden of women with a known risk of breast cancer receiving risk reducing medication.

Meagan S Whisenant, Jessica Treviño Jones, Anneliese O Gonzalez, Therese Bartholomew Bevers, Kelly Brassil, Darcy A Ponce, Sharvari Kamat, Emily Solis, Ann Maliackal, Hannah Warlick and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer treatment and research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Meagan S WhisenantDepartment of Behavioral Science, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, CPB3.3001, Houston, Texas 77030, USA. Electronic address: mswhisenant@mdanderson.org.
Jessica Treviño JonesDivision of Hematology/Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin, MSB 1.150, Houston, Texas 77030, USA.
Anneliese O GonzalezDivision of Hematology/Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin, MSB 1.150, Houston, Texas 77030, USA.
Therese Bartholomew BeversDepartment of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, CPB6.3500, Houston, Texas 77030, USA.
Kelly BrassilPack Health, a Quest Diagnostics Company, 110 12(th) Street North, Birmingham, Alabama, 35203, USA.
Darcy A PonceDepartment of Behavioral Science, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, CPB3.3001, Houston, Texas 77030, USA.
Sharvari KamatDepartment of Research, Cizik School of Nursing, The University of Texas Health Science Center at Houston, 6901 Bertner Avenue, Houston, Texas 77030, USA.
Emily SolisDepartment of Research, Cizik School of Nursing, The University of Texas Health Science Center at Houston, 6901 Bertner Avenue, Houston, Texas 77030, USA.
Ann MaliackalDepartment of Research, Cizik School of Nursing, The University of Texas Health Science Center at Houston, 6901 Bertner Avenue, Houston, Texas 77030, USA.
Hannah WarlickDepartment of Research, Cizik School of Nursing, The University of Texas Health Science Center at Houston, 6901 Bertner Avenue, Houston, Texas 77030, USA.
Amie WaltersDepartment of Research, Cizik School of Nursing, The University of Texas Health Science Center at Houston, 6901 Bertner Avenue, Houston, Texas 77030, USA.
Chloe DenhamDivision of Hematology/Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin, MSB 1.150, Houston, Texas 77030, USA.
Loretta A WilliamsDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, Texas 77030, USA.

Funding

UTMB Women's Health Research Scholars ProgramK12AR084228 · NIAMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ABBEY B BERENSON · 2023 to 2026
$2.7M
NIAMS NIH HHS K12 AR084228
6 · The paper itself

Abstract

backgroundFor the estimated 10 million women in the United States who meet the high-risk criteria for breast cancer, evidence-based interventions may reduce the risk of breast cancer by 50-65 %. Even with substantial evidence supporting preventive medication for risk reduction, there is significant lack of uptake and adherence. The purpose of this study was to characterize the experience of women at high risk for breast cancer and define the content domain for a patient-reported outcomes (PRO) measure of symptom burden from breast cancer risk and risk reducing medication.

methodsThirty women at high risk for breast cancer and receiving risk reducing medication participated in single qualitative interviews. Content analysis was used to identify the symptom burden. An expert panel review rated the relevance of symptoms identified in the qualitative interviews to establish the items for inclusion in a PRO symptom burden measure.

resultsParticipants had a mean age of 54.6 years; 43.3 % self-identified as Hispanic and 20.0 % self-identified as Black. Content analysis found 20 symptoms related to both risk and preventive treatment, with 8 symptoms reported by ≥ 20 % of women. All women described distress related to their risk and preventive care. Treatment-related symptoms varied based on history of risk-reducing surgery and type of endocrine therapy. Women described symptom-related interference with relationships, work, enjoyment of life, and adherence to risk reducing medication.

conclusionsWomen with a known high risk of breast cancer and receiving preventive care experience a unique symptom burden including multiple symptoms and functional impact related to symptoms.

Indexed as

Breast NeoplasmsAdultAgedCost of IllnessFemaleHumansMiddle AgedPatient Reported Outcome MeasuresQualitative ResearchRisk FactorsSymptom BurdenAntiestrogen therapyBreast cancerCancer preventionPatient-reported outcomesQuality of lifeSymptoms

Identifiers

PMID40252396
PMCPMC13317921

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.